GSK's AREXVY Vaccine Receives Expanded Approval In Canada For Adults Aged 50-59 At Increased Risk Of RSV, Offering Enhanced Protection Ahead Of Peak Season; Clinical Trials Ongoing For Adults 18-49
Dermatology Treatment and Care Market Research 2024-2030 Featuring Novartis, Pfizer, Amgen, GlaxoSmithKline, F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Merck & Co, Bayer, and Sanofi - ResearchAndMarkets.com
M&A Deals Roundup: AbbVie, Blackstone, Take-Two Interactive and More
GSK Cut to Neutral From Buy by Guggenheim
GSK Analyst Ratings
GSK Downgraded at Guggenheim After Q3 Sales Drop